who we are

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases. Our pipeline is one of the most innovative in the industry. During the past 10 years we have brought more than 15 new medicines or treated indications to patients in Finland.

KEY FACTS
CHIEF EXECUTIVE OFFICER Giovanni Caforio, M.D.
BUSINESS Biopharmaceuticals
NYSE LISTING BMY
NET SALES $15.9 billion in 2014
R&D INVESTMENT $4.5 billion in 2014
NUMBER OF EMPLOYEES 24,000

Bristol-Myers Squibb in Finland

  • Revenue around 15 million euros
  • 30+ employees
  • Studies in Finland about 17, study centers about 32, patients in studies 100
  • Innovative cancer studies in Finland: First patient in the world in two studies
  • Social responsibility: Hospital Clowns sponsored

what we do

In Finland we concentrate our efforts on promoting our medicines in specialty care to enable the treatment and cure of patients. We partner with Finnish healthcare institutions to help improve treatment outcomes. We are committed to launching and making available the new products coming from our pipeline as soon as possible after their authorization has been granted. Our therapeutic areas of focus include immuno-oncology, immunology, cardio-vascular, virology and hematology.

Contact information

www.bms.com/

Related posts